Impact of COVID-19 on Economy, Industry and Company :
The emergence of novel coronavirus has affected the global economy, industry dynamics and company’s top line. The entire ecosystem has to suffer the impact of this pandemic disease which would result in significant demand & supply gap, production delay and weak consumer demand of end products across industries. At Bizizz Market Research, our analyst has done extensive research across industries and identify various methodologies which would assist C-Level executive to counter this ongoing threat and make informed business decision.
Kindly contact us to know more details: https://www.bizizzmarketresearch.com/contact
"Global Eculizumab Market was Valued at US$ XX Mn in 2019 and it is Expected to Reach More than US$ 1023 Mn by 2028, Likely to Grow with the CAGR of 11.54% During the Forecast Period."
The Eculizumab is one of the medications used to cure paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS), they are also traded under the name of Soliris, and are promoted as medicines. The offering is a humanized monoclonal antibody which is a terminal complement inhibitor of the antibodies. The people who are affected with PNH, it decreases the elimination of red blood cells that are fatal and it requires a blood transfusion, and it shall not cause the risk of death. Eculizumab was the initial medication approved for its respective uses for various illnesses, and its approval was made based on small clinical trials. The Asia Pacific region is known as the fastest market growth for Eculizumb consumption globally. The application of Eculizumab is highly observed among the patients those who are suffering from PNH, aHUS and other illnesses.
Rising Healthcare Industry in developed countries to drive the Demand for Eculizumab:
An increase in the demand for Eculizumab is evident globally by an increase in the occurrence of the PNH and aHUS are contributing to its market growth. An increased number of patients suffering from various illnesses visiting the healthcare facilities are in need of different services that had also plunged the consumption of Eculizumba in the global market. The governments across the globe are also initiating various policies to support the individuals suffering from these illnesses had stimulated the healthcare industry in the global market.
aHUS Segment held a prominent share in Global Eculizumab Market in 2018
A significant proportion of Eculizumab consumption was observed among the patients of aHUS, and it has accounted for about 55% in 2016. It could be attributed to various chronic diseases and other environmental factors including long-term medications and continuous prone to pollution and their consumption which is evident in the recent years had plunged the demand of Eculizumba. There is a substantial amount of market growth of Eculizumab, especially by the aHUS suffering patients in the global platform. Therefore the global market is anticipated to have a substantial growth for eculizumab through aHUS segment.
North America Is expected to dominate the Eculizumab Market during the Forecast Period
The North America region is considered as the largest consuming region of Eculizumab, with a market share of approximately 40.3% in 2016. The North American region is followed by Europe accounted for the second-largest consumer of Eculizumab region and it had accounted with consumption rate of 32.6%. The North American market is anticipated to increase the consumption rate during the forecast period because of an increasing amount of chronic and environment caused health challenges.
Global Eculizumab market is consolidated with key players holding a major share of global Eculizumab market. The organizations offering Eculizumab are expanding their global presence by strategies such as mergers and acquisitions and investments with other organizations.
Key players operating in the global Eculizumab market are Intas Pharmaceuticals Limited, Jenburkt Pharmaceuticals Limited, Accure Labs Private Limited, Shilpa Medicare Ltd., Aaltop Healthcare Private Limited, Bioplus Life Sciences Private Limited, and RR Life Sciences.
Global Eculizumab Market Key Segments:
Global Eculizumab Market, By Type
- Plasma Exchange
- Plasma Infusion
Global Eculizumab Market, By Applications
Global Eculizumab Market, By Region
- North America
- Asia Pacific
- Middle east and Africa
- Latin America